Assessment of immunohistochemical Expression of HER2\Neu and BRCA1 in Colorectal Tumors and it's Correlation with Clinicopathological Variables
Keywords:
Immunohistochemical Expression-HER2\neu, BRCA1, Colorectal TumorsAbstract
Background: HER2\neu and BRCA1 expression in tumors is consider as a important prognostic marker in relation to the use of adjuvant therapy specially in a patients with worse prognosis in which that result in improvement in their survival. this research was done to assess the HER2\neu and BRCA1 immunohistochemical expression in colorectal tumors in correlation with some clinicopathological parameters. Methods: in this study(which was done retrospectively), A 44 cases include22 benign colonic lesions and 22 colonic adenocarcinoma in addition 6 normal resection (non tumors) margin were used as a control group, paraffin embedded archival materials from this cases were collected for the period between Nov 2015- July 2016.the expression of 2 markers (HER2/neu and BRCA1)were assessed and then were correlated with different clinicopathological parameters . Results: the immunohistochemical expression of HER2\neu was (45%) of CRC, in (27%) of colorectal polyps and in (4) out of (6) non-neoplastic colonic tissues. HER2\neu was expressed more frequently in the colon in about (46%),in female (39%), in the age group of more than 40 years (43%) , in well differentiated adenocarcinoma (67%), in non mucinous adenocarcinoma (90%), in T2 (54%) and the tumor size of more than 4 cm (66%) although the results were statistically not significant.. BRCA1 immunostaining was found in (6%) of colorectal tumor and there were (14%) positive cases of colorectal polyps, the result was statistically not significant. BRCA1 expressed more frequently in the colon (20%), in male (8%) and age group of more than 40 years(10%) the results were statistically not significant. there was no difference in BRCA1 expression between tumor size of more or less than 4 cm . Conclusions: In this study researchers concluded that expression of HER2\neu in colorectal tumors (benign and malignant) is not infrequent phenomena , HER2\neu expression was obviously increased in non-neoplastic tissues and adenoma, Low expression of BRCA1 in colorectal tumors and no significant correlation of BRCA1 expression in relation to the clinicopathological parameter (age, gender, tumors types, site and size).References
World Health Organization. February 2014. Retrieved 24 May 2015.
National Cancer Institute. 2014.
Report of Iraq Cancer Registry, Ministry of health, Baghdad- Iraq, 2012.
Baselga J, Mendelsohn J: The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 1994, 29:127-138.
Garcia JM, Rodriguez R, Dominguez G. Prognostic significance of the allelic loss of the BRCA1gene in colorectal cancer. Gut 2003; 52:1756-63.
Berczi C; Bocsi J.; Bartha I.; Math J.; Balazs G.: Prognostic value of DNA ploidy status in patients with rectal cancer. Anticancer Res. 2002; 22(68):3737-41.
Slamon DJ, Clark GM. Amplification of C-ERB-B2 and aggressive breast tumors. Science 1988; 240: 1795-1798.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Salamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ et, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 2000; 20:719-26.
Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN: Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001; 120:1713-9.
Hall J, Lee M, Newman B, Morro J, Anderson L, Huey B, Linkage of early onset familial breast cancer to chromosome 17q21. Science, 1990, 250: 1684-9.
Futreal P A, Soderkvisi P, Marks J R, Iglehart J D, Cochran C, Barrett J C and Wiseman R W. Detection of frequent allelic loss on proximal 17q in sporadic breast carcinoma using microsatellite length polymorphisms; Cancer Res. 1992, 52 2624–2627.
Rahman N, Stratton MR: The genetics of breast cancer susceptibility. Annu Rev Genet 1998; 32:95–121.
Brose MS, Rebbeck TR, Calzone KA.: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Nat Cancer Inst 2002; 94 (18): 1365-72.
Thompson D and Easton DF; Breast Cancer Linkage Consortium.: Cancer Incidence in BRCA1 mutation carriers. J Nat Cancer Inst 2002; 94 (18): 1358-65.
Brose MS, RebbeckTR, Calzone KA. Cancer risk estimates for BRCA1mutation carriers identified in a risk evaluation program. J Nat l Cancer Inst 2002; 94:1365 - 72.
Galandiuk S, Miseljic S, Yang AR, Early M, McCoy MD, Wittliff JL. Expression of hormone receptors, cathepsin D, and HER-2/neu oncoprotein in normal colon and colonic disease. Arch Surg. 1993 Jun;128(6):637–642.
Ghaffarzadegan K., Sharifi N., Vosooghynia H., Shakeri T., Ghiasi T. Moghadam,Sh. Ghanad Kafi, Lari S., Nassiri. G.; HER2/neu expression in colon adenocarcinoma and its correlation with clinicopathologic variables. 2006;20:66-80.
,Heike Grabsch, Mit Dattani, Lisa Barker,NicolaMaughan,KarenMaude,Olaf Hansen,Helmut E. Gabbert, Phil Quirke,and WolframMueller. Expression of DNA Double-Strand Break Repair Proteins ATM and BRCA1Predicts Survival in Colorectal Cancer. Clin Cancer Res 2006; 12(5).
A1-Bahrani ZR , Al Hadithi RH , Al Bahrani AZ . Colorectal carcinoma In Iraq: Clinicopathological study. The Arab JG, October 2003;4 :104-110.
Al-Humadi.A H. Epidemiology of Colon & Rectal Cancer In Iraq ,World Journal of Colorectal Surgery2008;15:20-22
Naim H. Expression of B-HCG and its pathological Aspect in Colorectal carcinoma .A thesis submitted to the scientific council of pathology as a partial fulfillment of the requirement for the degree of board in pathology 2005
Kakill R, Abdullah SA, Ahmed AM & Ussama M. study of colorectal cancer in Qatar. Saudi Med J 2001; 22(8): 705-707.
Isbister WH. Malignant neoplasm of colon, rectum and anus at the king Faisal specialist Hospital & Research centre. Ann Saudi/ Med 1992; 12 (5): 429-433.
Ibrahim M, Ibrahim HZ & Syed AR. Colorectal cancer in Saudi Arabia. Saudi Med J, 2002; 33:322-326.
Isbister WH & Fraser J. Survival following resection for colorectal cancer. Dis colon rectum 1985; 28:725-72.
H. Darwish, I. E. Trejo, I. Shapira, S. Oweineh, M. Sughayer, L. Baron, E. Aljadeff,M. colorectal cancer: molecular epidemiology differences among Ashkenazi and Sephardic Jews and Palestinians. Annals of Oncology 2002;13: 1497–1501
Berczi C; Bocsi J.; Bartha I.; Math J.; Balazs G.: Prognostic value of DNA ploidy status in patients with rectal cancer. Anticancer Res. 2002; 22(68):3737-41
Kathryn LS, Michael JS, and Danel R. Review of colorectal cancer in patients under age 40 years. Am J Surg, 1981; 142:767-769.
Half E., Broaddus R., Danenberg K. D., Danenberg P. V., Ayers G. D., Sinicrope F. A. HER2 receptor expression, localization ,and activation in colorectal cancer cell lines and human tumors, Int. J. Cancer 2004; 108: 540-8.
Toshikatsu Osako, Masaki Miyahara, Shinya Uchino, Masafumi Inomata, Seigo Kitano, Michio Kobayashi. Immunohistochemical Study of c-erbB-2 Protein in Colorectal Cancer and the Correlation with Patient Survival.: 1998; 55:548-555.
Nathanson DR, Culliford AT 4th, Shia J, Chen B, D'Alessio M, Zeng ZS, Nash GM, Gerald W, Barany F, Paty PB.: HER 2/neu expression and gene amplification in colon cancer. Int J Cancer. 2003 Jul 20; 105(6):796-802.
Park D. I., Oh S. J., Park S. H., Yun J. W. Clinical significance of HER-2/neu expression in colon cancer, Korean J. Gastroenterol. 2004; 44:147-52.
Wen Jin, Mei-Qin Gao, Zhi-Wu Lin, Dai-Xing Yang. Quantitative study of multiple biomarkers of colorectal tumor with diagnostic discrimination model. World J Gastroenterol 2004; 10(3):439-442.
Marek Pazurek, Beata Smolarz, Hanna Romanowicz-Makowska, Andrzej Kulig, Ewa Małecka-Panas.: Overexpression of HER-2/neu in patients with colorectal cancer (CC) and colorectal adenomas (CP) 2009; 50(3):179-182.
Eliane C. Jesus; Delcio Matos; Ricardo Artigiani; Angela F.L. Waitzberg; Alberto Goldenberg; Sarhan Sydney Saad. Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins.: Nov./Dec. 2005; 0102-8650.
Irena Porebska, Antonina Haroziska, Tomasz Bojarowski.: Expression of the Tyrosine Kinase Activity Growth Factor Receptors (EGFR, ERB B2, ERB B3) in Colorectal Adenocarcinomas and Adenomas. Tumor Biol 2000; 21:105-115.
McKay J. A., Loane J. F., Ross V. G., et al. C-erbB2 is not a major factor in the development of colorectal cancer, Br. J. Cancer 2002; 86: 568-73.
SchuellB,Gruenberger,Scheisauer,Zielinski,Wrba.: HER 2/neu protein expression in colorectal cancer. BMC CANCER 2006 May; 8;6:123
Nathanson DR, Culliford AT 4th, Shia J, Chen B, D'Alessio M, Zeng ZS, Nash GM, Gerald W, Barany F, Paty PB.: HER 2/neu expression and gene amplification in colon cancer. Int J Cancer. 2003 Jul 20; 105(6):796-802.
Park D. I., Oh S. J., Park S. H., Yun J. W. Clinical significance of HER-2/neu expression in colon cancer, Korean J. Gastroenterol. 2004; 44:147-52
Aylar Poyraz, Ozlem Suer, Cem Sezer and Gulen Akyol.: Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. February 28, 2009; 7: 24-27.
Galandiuk S, Miseljic S, Yang AR, Early M, McCoy MD, Wittliff JL. Expression of hormone receptors, cathepsin D, and HER-2/neu oncoprotein in normal colon and colonic disease. Arch Surg. 1993 Jun;128(6):637–642.
Wen Jin, Mei-Qin Gao, Zhi-Wu Lin, Dai-Xing Yang. Quantitative study of multiple biomarkers of colorectal tumor with diagnostic discrimination model. World J Gastroenterol 2004; 10(3):439-442.
Ross J. S., McKenna. TheHER-2/neu oncogene in tumors of the gastrointestinal tract, Cancer Invest 2001; 19: 554-68.
Garcia-Patio E, Gomendio B, Lleonart M, Silva JM, Garcia JM, Provencio M, Cubedo R, Espaa P, Ramn y Cajal S, Bonilla . Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer. Cancer Genet Cytogenet. 1998 Jul 15; 104(2):119-23.
Bethany L. Niell, Gad Rennert, Joseph D. Bonner, Stephen B. Gruber. RESPONSE: Re: BRCA1 and BRCA2 Founder Mutations and the Risk of Colorectal Cancer (2004): 96(15):1185-1186
K Ishiguro, T Yoshida, H Yagishita, Y Numata, and T Okayasu. Epithelial and stromal genetic instability contributes to genesis of colorectal adenomas.2006 May; 55(5): 695–702.
